Choose a PT-141 mini troche for one compact oral-dissolve step built around centrally acting desire biology. Rebody's 2 mg mini troche comes in a refrigerated 8-count package.
The short answer
PT-141 troches contain bremelanotide in a solid dosage form designed to dissolve under the tongue or between gum and cheek. They make the routine needle-free, pump-free, compact, and private. Direct clinical outcome research has not yet tested the Rebody finished troche.
Rebody sells one strength, 2 mg. The dispensing instructions provide timing, dissolve expectations, food and drink rules, maximum use, days of supply, and refill cadence.
The troche at a glance
| Product fact | 2 mg mini troche |
|---|---|
| Active | Bremelanotide |
| Package | 8 troches |
| Placement | Sublingual or buccal as prescribed |
| Storage | Refrigerated |
| Route-specific outcome trial | None identified |
| Status | Available · $59.50 first month, then $119 per 8-count package |
Ten dosage units do not establish ten days, one month, or ten prescribed uses without the final maximum frequency and supply contract.
What a mini troche is
A troche is designed to dissolve in the mouth rather than be swallowed immediately like a standard tablet. Sublingual placement means beneath the tongue. Buccal placement means between gum and inner cheek.
Some active may cross oral mucosa and some may be swallowed. The balance depends on the formula, base, contact time, saliva, and behavior. “Sublingual” does not guarantee complete absorption or an injection-like exposure curve.
Do not chew, move the troche to the top of the tongue, or swallow it early unless the dispensing instructions allow it.
One strength
Rebody sells the 2 mg mini troche. A clinician decides whether it fits after reviewing your visit.
Do not cut a troche in half unless the product is scored and instructions expressly permit it. Drug distribution and physical stability may not make a homemade half equivalent to a smaller unit.
Why the bremelanotide evidence matters
In the two 24-week RECONNECT trials, 1,267 premenopausal women with acquired, generalized HSDD were randomized to 1.75 mg subcutaneous bremelanotide or placebo.
The injection improved desire and distress measures versus placebo, establishing bremelanotide as a real desire medication rather than another blood-flow product. The troche prescription supplies its own oral-route timing, dose frequency, and instructions.
No direct outcome trial identified in this research gave participants Rebody's 2 mg troche.
PT-141 is about desire, not only blood flow
Bremelanotide acts through melanocortin receptors in the central nervous system. The approved indication concerns low sexual desire and associated distress in a defined female population.
Sildenafil and tadalafil target a blood-flow pathway used for erection. A troche should not be sold as “sublingual Viagra” or a guaranteed erection medication.
It also should not promise orgasm, lubrication, performance, relationship repair, or automatic desire. Those claims go beyond what the injection trials measured.
Placement under tongue or in cheek
The prescription may specify sublingual or buccal placement. The areas feel different, produce different saliva exposure, and can change how easy it is to speak or drink while the troche dissolves.
Use one consistent approved placement when learning the routine. Do not move the troche around repeatedly or add another because dissolution feels slow.
Mouth sores, recent dental procedures, gum disease, severe dry mouth, or irritation can change tolerability and deserve route-specific guidance.
Dissolve time, food, and drink
There is no universal 10-, 20-, or 30-minute dissolve time. Troche base, flavor, placement, and saliva can change the experience; use the instructions supplied with the package.
The finished directions will state whether eating, drinking, brushing teeth, or rinsing must be separated from use. What is confirmed now is placement beneath the tongue or between the gum and cheek; the remaining routine details are not yet settled.
If the troche is accidentally swallowed, follow the final missed-use or administration guidance. Do not immediately take another.
Timing before intimacy
The approved injection label says Vyleesi is used at least 45 minutes before anticipated sexual activity. That is an injection instruction, not a troche instruction.
Troche dissolution and absorption may create a different timeline. Online reports vary too widely to establish a reliable onset, and expectation can influence perceived effect.
Use the final prescribed lead time. Do not redose because an injection-based countdown has passed.
Refrigeration and travel
The troches are refrigerated. Keep the labeled 8-count package protected from freezing, moisture, crushing, and heat. Do not move troches into a room-temperature pill organizer unless product instructions allow it.
For travel, ask about permitted time outside refrigeration and use a carrier that avoids direct ice contact. Keep the prescription label visible.
Softening, wetness, cracking, discoloration, sticking, or damaged seals should be checked before use. Do not reshape or combine damaged pieces to estimate a dose.
Side effects and active-level warnings
The Vyleesi label reports nausea as the most common adverse reaction and also addresses flushing, headache, vomiting, blood-pressure increases, heart-rate reduction, focal hyperpigmentation, pregnancy, delayed gastric emptying, and oral naltrexone exposure.
Troches can add mouth irritation, taste, altered sensation, or gastrointestinal questions. Route-specific rates are not established.
Uncontrolled hypertension and known cardiovascular disease are contraindications on the approved injection label. A troche does not make those active-level questions disappear. Chest pain, fainting, severe allergy, a concerning blood-pressure reaction, or a prolonged painful erection requires urgent attention.
Interactions and maximum frequency
Bremelanotide can delay gastric emptying and reduce exposure to oral naltrexone according to the approved label. An oral troche does not make those active-level questions disappear.
The injection limit of one dose per 24 hours and eight per month is not a troche instruction. Use the frequency printed on the troche prescription.
Do not create public protocols combining PT-141 with Viagra, Cialis, alcohol, or anti-nausea medication.
Price, count, and refill rhythm
The 2 mg PT-141 troche is $59.50 first month, then $119 per 8-count package. Days of supply remain prescription-specific. An 8-count package could represent different durations depending on prescribed timing and maximum use.
Before starting, confirm strength, count, prescribed uses, storage, package price, and refill timing. Those facts matter more than cost per milligram.
An 8-count jar is not automatically a one-month supply because prescribed timing varies.
Questions people ask
What makes PT-141 troches compelling?
They put a centrally acting desire medication into a compact sublingual or buccal form without a needle, nasal pump, or liquid bottle. Human bremelanotide trials established improved desire and distress with injection; direct Rebody troche outcomes remain the next route-specific evidence question.
Should a troche be swallowed?
It is designed for sublingual or buccal dissolution as prescribed, not immediate swallowing.
What strength is the troche?
Rebody sells the 2 mg mini troche. Your clinician decides whether it fits.
How long does it take?
No approved troche onset is established. Do not copy the injection's 45-minute instruction.
Can troches be cut?
Only if the dispensing instructions explicitly permit it. Do not assume uniform drug distribution or stability.
Bottom line
PT-141 mini troches turn bremelanotide's centrally acting desire biology into one compact oral-dissolve step. Keep the 8-count package refrigerated, and follow the product-specific placement, timing, and maximum-use instructions. Choose this form for a private needle-free, pump-free intimacy routine.
Keep exploring PT-141
- Compare every needle-free PT-141 format
- See the PT-141 nasal spray strength guide
- Read PT-141 nasal spray vs troche
- See the PT-141 troche product
Primary sources
- FDA. Vyleesi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
- Kingsberg SA, Clayton AH, Portman D, et al. RECONNECT phase 3 trials. https://pubmed.ncbi.nlm.nih.gov/31599840/